Cytovax Biotechnologies Inc. is a biotechnology company focused on the development of novel approaches for the prevention and treatment of infectious diseases.
Cytovax is developing new, effective weapons in the fight against infectious diseases. Cytovax's products act through a mechanism that is different from that of current anti-infectives, such as antibiotics, which are designed to kill bacteria directly. The company's proprietary "Anti-Adhesin Technology" prevents infection by blocking the adhesion of pathogens onto human mucosal cells, thus preventing the onset of the infection process, and, accordingly, the antibiotic resistance of the pathogen has no impact on the effectiveness of these anti-adhesin products. Peptide vaccines and monoclonal antibody therapeutics are being developed using this innovative technology to prevent and treat a wide range of pathogens, including Pseudomonas aeruginosa, Streptococcus pneumoniae and other infectious agents that initiate infection in a similar manner. Cytovax's technology has the potential to be a key weapon in the fight against antibiotic-resistant bacteria.
Cytovax's lead product, Cytovaxine™, a consensus sequence peptide, will be used to prevent the intitiation of Pseudomonas aeruginosa infection process through vaccination. Pseudomonas aeruginosa is amoung the leading causes of hospital-acquired pneumonia, and in 35% to 45% of infections, the organism is resistant to the best drug that would normally be chosen to treat that organism.
As an alternative to vaccination and for situations where the patient is at immediate risk of infection, Cytovax plans to use its proprietary technology to treat diseases through the introduction of monoclonal antibodies. Cytovax is currently in the pre-clinical phase for a monclonal antibody therapeutic for Pseudomonas aeruginosa, and has demonstrated the effectiveness of the therapeutic in mice subjected to a lethal dose of Pseudomonas aeruginosa.
Cytovax anticipates that it will choose Streptococcus pneumoniae as its second target product, and may seek to develop both a vaccine and monoclonal antibody therapeutic to prevent and treat this disease.
| Contact Details: |
| 8223 Roper Road, |
| Edmonton |
| Alberta |
| T6E 6S4 |
| Canada |
| Tel: | (780) 448-0621 |
| Fax: | (780) 448-0624 |
| Email: | biotech@cytovax.com |
| WWW: | www.cytovax.com/
|
|
Loading...
|
Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.
This page has been viewed 242 times since April 2007, the link to the organisation's website has been followed 65 times
Recent Search Terms used to find this page: Cytovax Biotechnologies | Cytovax Biotechnologies canada | Cytovax biotechnologies | cytovax.com | Streptococcus vaccine cytovax | Pseudomonas aeruginosa facts | millenium biologix pneumoniae | cytovax pseudomonas | cytovax | cytovax.com | .
Search for more companies in Edmonton
Search for more companies in Alberta
This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.BioPortfolio search results for
Cytovax Biotechnologies Incorporated
